TheraSphere™ Y-90 in HCC: From evidence to precision treatment
Y-90 radioembolization continues to evolve as an important treatment option for hepatocellular carcinoma (HCC), with growing evidence supporting increasingly personalized approaches to patient selection, dosimetry, and treatment planning. This webinar will explore how Y-90 fits across different HCC clinical scenarios, with a particular focus on curative-intent radiation segmentectomy, contemporary dosimetry and techniques principles, and insights from the PROACTIF real-world study. Faculty will discuss how tumour dose, microsphere characteristics, and procedural considerations can influence treatment strategy and impact oncological outcomes in liver cancer patients’ response.
Through expert presentations and interactive case discussions, participants will examine how clinical evidence, and technical planning can be translated into multidisciplinary decision-making and everyday practice. Cases addressing early-stage HCC and large tumours with portal vein thrombosis will highlight practical considerations for selecting appropriate patients and optimizing treatment execution. This CIRSE webinar, conducted in collaboration with Boston Scientific, aims to strengthen evidence-based decision-making and provide practical guidance on the use of TheraSphere in contemporary HCC management.
Learning objectives
- Explore current clinical experience with Y-90 radioembolization and identify the key clinical scenarios in which it is commonly utilized.
- Explain the principles and clinical rationale of radiation segmentectomy, including advances in Y-90 treatment planning and optimization.
- Evaluate the impact of tumour-absorbed dose, microsphere characteristics, and treatment delivery techniques on therapeutic strategy and clinical outcomes.
- Interpret findings from the PROACTIF real-world study and discuss their implications for patient selection and treatment strategies across different hepatocellular carcinoma (HCC) scenarios.
- Integrate patient selection criteria, dosimetry, and procedural considerations to support evidence-based, multidisciplinary decision-making in Y-90 radioembolization.
- Apply current clinical evidence and technical insights to evaluate and justify Y-90 treatment approaches in early-stage HCC and large HCC with portal vein thrombosis (PVT).
Programme
Introduction by the moderator
Laura Crocetti (Pisa/IT)
Curative-intent radiation segmentectomy: evidence and dosimetry
Tyler Sandow (New Orleans/US)
Who benefits from Y-90? PROACTIF and patient selection
Boris Guiu (Montpellier/FR)
Y-90 in practice: MDT decisions and treatment execution
Max Seidensticker (Munich/DE)
The Y-90 challenge: Interactive case discussions and Q&A
Laura Crocetti (Pisa/IT)
Take-home points by the moderator
Laura Crocetti (Pisa/IT)
Faculty
Moderator

Speakers




Join free of charge!
Access to this webinar is available free of charge to all interested parties. All you need is your myCIRSE login details. Don’t have a myCIRSE account yet? Not to worry! It only takes two minutes to set up a new account which will enable you to register.
This sponsored webinar is brought to you by Boston Scientific. Sponsored webinars are developed by a corporate partner and organized with the support of CIRSE.